Low-molecular-weight heparin is replacing unfractionated heparin for initial VTE treatment due to its suitability for outpatient therapy and lower risk of complications like HIT and osteoporosis.
Does low-molecular-weight heparin improve safety and efficacy compared to unfractionated heparin in the initial treatment of venous thromboembolism?
LMWH is the preferred initial anticoagulant for VTE due to its safety profile, predictable response, and suitability for outpatient therapy.
Adequate initial anticoagulant therapy of deep venous thrombosis (DVT) is required to prevent thrombus growth and pulmonary embolism (PE). Intravenous unfractionated heparin (UFH) is being replaced by low-molecular-weight heparin (LMWH) as the anticoagulant of choice for initial treatment of venous thromboembolism (VTE). Both agents are relatively safe and effective when used to treat VTE, with LMWH suitable for outpatient therapy because of improved bioavailability and more predictable anticoagulant response. Serious potential complications of heparin therapy, such as heparin-induced thrombocytopenia (HIT) and osteoporosis, seem less common with LMWH. The potential for fetal harm and changes in maternal physiology complicate the treatment of VTE during pregnancy. Although systemic thrombolysis is used in patients with massive PE and in some patients with proximal DVT, controversy persists with respect to appropriate patient selection for this intervention.
McRae et al. (Mon,) conducted a review in Venous Thromboembolism. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin (UFH) was evaluated. Low-molecular-weight heparin is replacing unfractionated heparin for initial VTE treatment due to its suitability for outpatient therapy and lower risk of complications like HIT and osteoporosis.